Celldex: ASCO Investor Event (Celldex) - Jun 1, 2015 - “Rindopepimut was very well tolerated without additive toxicity to bevacizumab”; “Bevacizumab-naive patients: The randomized Phase 2 study met its primary endpoint of PFS6: 28% vs 16% (p = 0.1163), Overall survival advantage (HR=0.57, p=0.0386) with apparent long-term survival benefit, Advantage to rindopepimut therapy across multiple endpoints including long-term progression-free survival, objective response rate and steroid requirement”; “Bevacizumab-refractory patients: Evidence of rare and prominent tumor regression, Up to 11% objective response rate”; “Activity profile consistent with prior immunotherapy experience”; “Remarkable frequency and level of anti-EGFRvIII immune responses despite prior chemotherapy and growing tumor, Development of anti-EGFRvIII titer may be a biomarker of improved outcome”
P2 data • Oncology
|